Wilmington PharmaTech (“Wilmington”), a leading U.S.-based research, development, and manufacturing organization (CRDMO) focused on complex custom small-molecule API production, today announced a $50 ...

Throughout 2025, drugmakers of all stripes have collectively poured billions of dollars into U.S. manufacturing investments. Many of those projects have centered on later stages of the production ...

Eli Lilly and Company (Lilly) plans to construct an active pharmaceutical ingredient (API) manufacturing facility, totaling around 1 million square feet, in Harris County, Texas. According to news ...

Advancing small molecules from R&D to GMP requires coordinated strategies to support phase I clinical manufacturing.

Eurofins CDMO Alphora is excited to announce the expansion of its Active Pharmaceutical Ingredient (API) manufacturing capabilities through the integration of advanced, custom-built Continuous Flow ...

Raubling, Germany-based Axplora, which focuses on small-molecule API manufacturing reports that its total investments initiated across its global network in 2025 will exceed €100 million ($115.6 ...